Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Shanghai 200092

9 studies enrolling now · 16 studies all time

What they study most

ALK Fusion-positive Solid or CNS Tumors, Alzheimer Disease, Atopic Dermatitis, Carcinoma, Transitional Cell, Colorectal Cancer, Eczema, Inherited Retinal Diseases, Metabolic Dysfunction-Associated Steatotic Liver Disease, Metastatic Breast Cancer, Metastatic Cholangiocarcinoma, Moderately to Severely Active Crohns Disease, Moderately to Severely Active Ulcerative Colitis

Studies at this site

• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) — Recruiting now
• A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors — Recruiting now
• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema — Recruiting now
• A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema — Recruiting now
• Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation — Recruiting now
• A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression — Recruiting now
• A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD — Recruiting now
• Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study — Running, not enrolling
• Global Patient Registry of Inherited Retinal Diseases — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma — Stopped early
• Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer — Completed
• Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD) — Stopped early
• A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection — Stopped early
• A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer — Completed